Voyage is hiring Clinical Staff - contact us to find out more!


pexels olly 846080 1 by Voyage Healing in Philadelphia, PA


SPRAVATO® (esketamine) is an FDA approved version of ketamine, offering rapid and effective treatment outcomes. Generic ketamine contains two mirror molecules, called   S-ketamine and R-ketamine.  Spravato is the isolated S-ketamine molecule administered intranasally at the clinic, and involves two hours of monitoring.  Insurance often covers Spravato for appropriate patients.

When using SPRAVATO®, it is combined with an oral antidepressant. Unlike standard antidepressants, SPRAVATO® does not require daily usage; instead, it can be taken anywhere from twice weekly to monthly.

To gain further insight into this treatment option, schedule a complimentary informational call with one of our health navigators.

Who is this approved for?

  • Individuals diagnosed with treatment-resistant depression (defined as those who have not responded adequately to two or more antidepressant medications).
  • Adults diagnosed with Major Depressive Disorder who are encountering suicidal ideation or behaviors.

How does it work?

SPRAVATO® approaches depression treatment differently from conventional antidepressants, and represents a new mechanism of action. Unlike most traditional medications, which operate on serotonin and neuroepinephrine, S-ketamine, the active ingredient in SPRAVATO®, targets the N-methyl-D-aspartate (NMDA) receptor. This action leads to heightened glutamate activity in the brain. Researchers hypothesize that this process facilitates the formation of new neural connections, potentially enabling the development of positive thought patterns and behaviors in patients undergoing ketamine treatment—a phenomenon often termed neuroplasticity. 

pexels sanaan 3075945 by Voyage Healing in Philadelphia, PA